PMID- 29902977
OWN - NLM
STAT- MEDLINE
DCOM- 20180717
LR  - 20220408
IS  - 1471-2415 (Electronic)
IS  - 1471-2415 (Linking)
VI  - 18
IP  - 1
DP  - 2018 Jun 15
TI  - Conbercept for patients with age-related macular degeneration: a systematic 
      review.
PG  - 142
LID - 10.1186/s12886-018-0807-1 [doi]
LID - 142
AB  - BACKGROUND: Conbercept is a novel vascular endothelial growth factor (VEGF) 
      inhibitor for the treatment of wet age-related macular degeneration (AMD). This 
      systematic review aims to assess the efficacy and safety of conbercept in the 
      treatment of wet AMD. METHODS: PubMed, Embase, Cochrane Library, China National 
      Knowledge Infrastructure, VIP database, and Wanfang database were searched from 
      their earliest records to June 2017. We included randomized controlled trials 
      (RCTs) evaluating the efficacy and safety of conbercept in wet AMD patients. 
      Outcomes included the mean changes from baseline in best-corrected visual acuity 
      (BCVA) score (primary outcome), central retinal thickness (CRT), plasma level of 
      vascular endothelial growth factor (VEGF) over time, and the incidence of adverse 
      events (AEs). RESULTS: Eighteen RCTs (1285 participants) were included in this 
      systematic review. Conbercept might improve BCVA compared to triamcinolone 
      acetonide [MD = 0.11, 95% CI (0.08, 0.15)], and reduce CRT compared to the other 
      four therapies (conservative treatment, ranibizumab, transpupillary 
      thermotherapy, and triamcinolone acetonide). The incidence of AEs in patients 
      receiving conbercept was significantly lower than those receiving triamcinolone 
      acetonide [RR = 0.25, 95% CI (0.09-0.72)], but was similar to the other 
      therapies. Conbercept seemed to be more effective than ranibizumab in lowering 
      the plasma level of VEGF [MD = - 15.86, 95% CI (- 23.17, - 8.55)]. CONCLUSIONS: 
      Current evidence shows that conbercept is a promising option for the treatment of 
      wet AMD. Nevertheless, further studies are required to compare the efficacy, 
      long-term safety and cost-effectiveness between conbercept and other anti-VEGF 
      agents in different populations.
FAU - Zhang, Jiaxing
AU  - Zhang J
AD  - Department of Pharmacy, Guizhou provincial people's hospital, No.83 Zhongshandong 
      Road, Nanming District, Guiyang, Guizhou Province, China.
FAU - Liang, Yi
AU  - Liang Y
AD  - Health Outcomes and Pharmacy Practice, College of Pharmacy, the University of 
      Texas at Austin, Austin, Texas, USA.
FAU - Xie, Juan
AU  - Xie J
AD  - Department of Pharmacy, Guizhou provincial people's hospital, No.83 Zhongshandong 
      Road, Nanming District, Guiyang, Guizhou Province, China.
FAU - Li, Dong
AU  - Li D
AD  - Department of Ophthalmology, Guizhou provincial people's hospital, Guiyang, 
      Guizhou Province, China.
FAU - Hu, Qian
AU  - Hu Q
AD  - Department of Ophthalmology, Guizhou provincial people's hospital, Guiyang, 
      Guizhou Province, China.
FAU - Li, Xiaosi
AU  - Li X
AD  - Department of Pharmacy, Hospital of Chengdu Office of People's Government of 
      Tibetan Autonomous Region, No.20 Ximianqiaoheng Street, Wuhou District, Chengdu, 
      Sichuan Province, China. lixiaosiyyy@126.com.
FAU - Zheng, Wenyi
AU  - Zheng W
AD  - Department of Laboratory Medicine, Experimental Cancer Medicine, Clinical 
      Research Center, Karolinska Institute, 14186, Huddinge, Stockholm, Sweden.
FAU - He, Rui
AU  - He R
AD  - Department of Laboratory Medicine, Experimental Cancer Medicine, Clinical 
      Research Center, Karolinska Institute, 14186, Huddinge, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20180615
PL  - England
TA  - BMC Ophthalmol
JT  - BMC ophthalmology
JID - 100967802
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 1P05PW62F3 (KH902 fusion protein)
SB  - IM
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Intravitreal Injections
MH  - Recombinant Fusion Proteins/*administration & dosage
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
MH  - *Visual Acuity
MH  - Wet Macular Degeneration/*diagnostic imaging/drug therapy/physiopathology
PMC - PMC6003117
OTO - NOTNLM
OT  - Conbercept
OT  - Ranibizumab
OT  - Systematic review
OT  - Vascular endothelial growth factor (VEGF) inhibitor
OT  - Wet age-related macular degeneration
COIS- AUTHOR'S INFORMATION: The submitting author: Jiaxing Zhang. Postal Address: No.83 
      Zhongshandong Road, Nanming District, Guiyang, Guizhou Province, China. ETHICS 
      APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. No ethical issues were 
      involved in this study given that our data were based on published studies. 
      Written informed consent for participation and ethical approval has been provided 
      by original studies. Thus, all investigations analyzed in this meta-analysis have 
      been carried out in compliance with the Helsinki Declaration. COMPETING 
      INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S 
      NOTE: Springer Nature remains neutral with regard to jurisdictional claims in 
      published maps and institutional affiliations.
EDAT- 2018/06/16 06:00
MHDA- 2018/07/18 06:00
PMCR- 2018/06/15
CRDT- 2018/06/16 06:00
PHST- 2017/12/06 00:00 [received]
PHST- 2018/05/30 00:00 [accepted]
PHST- 2018/06/16 06:00 [entrez]
PHST- 2018/06/16 06:00 [pubmed]
PHST- 2018/07/18 06:00 [medline]
PHST- 2018/06/15 00:00 [pmc-release]
AID - 10.1186/s12886-018-0807-1 [pii]
AID - 807 [pii]
AID - 10.1186/s12886-018-0807-1 [doi]
PST - epublish
SO  - BMC Ophthalmol. 2018 Jun 15;18(1):142. doi: 10.1186/s12886-018-0807-1.